Suzhou Maximum Bio-tech Co., Ltd. is recruiting patients for a PHASE1 clinical trial testing CAR-T cell therapy for mesothelioma.
The trial, designated NCT06726564, aims to enroll up to 18 participants at 1 sites.
About the Study
This is a phase I open label, single-arm, dose-escalation study to evaluate the feasibility, safety, tolerability, PK/PD, and to determine RP2D of MT027 via an locoregional delivery in subjects with pleural malignant tumors, who have previously received standard of care therapy..
Subjects meeting the study entry criteria including having tumor antigen B7H3 overexpression via immunohistochemistry (IHC ) will be enrolled and assigned to cohorts sequentially to receive study treatments, assessments, as well as post-treatment safety follow-ups in the study.
Treatment Approach
This trial uses genetically engineered T cells that target mesothelin on mesothelioma cells.
Key trial details:
- Phase: PHASE1
- Sponsor: Suzhou Maximum Bio-tech Co., Ltd.
- Enrollment target: 18
- Status: RECRUITING
Why This Trial Matters
CAR-T cell therapy has revolutionized treatment for blood cancers, and researchers are working to adapt this approach for solid tumors like mesothelioma.
Study Locations
Contact the trial sponsor for information about participating sites.
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening